OVERVIEW

Updates on PD-L1 and the Companion Diagnostic Landscape is organized by National Society for Histotechnology (NSH) and will be held on Sep 17, 2025.

Description:
IHC based Companion Diagnostics are key enablers of Precision Medicine and have drastically changed the pathology practice. PD-L1, or programmed death-ligand 1, is a critical biomarker that is used to predict responses to certain immunotherapies. Multiple PD-L1 IHC assays have been approved by the FDA as companion diagnostics and are critical to determine the PD-L1 expression levels in different tumors. In this presentation we will review recent updates on the PD-L1 testing landscape and discuss best laboratory practices for PD-L1 testing.